Harrow Strategy and Business Model

Executive Overview

Harrow is a U.S.-focused ophthalmic pharmaceutical company headquartered in Nashville, Tennessee. The company traces its roots to 2006 and has evolved from an ophthalmic compounding platform into a more scaled branded eye-care business. Its strategy is centered on acquiring, licensing, developing, and commercializing prescription ophthalmic products that matter to a concentrated set of eye-care call points: ophthalmologists, optometrists, ambulatory surgery centers, hospitals, pharmacies, and ultimately patients. By 2024, Harrow’s portfolio included newer growth assets such as VEVYE for dry eye disease and IHEEZO for ocular-surface anesthesia, alongside a larger collection of established ophthalmic prescription brands in anti-inflammatory, anti-infective, anti-allergy, anti-fungal, and surgical categories.

What makes Harrow strategically distinctive is that it is not trying to compete as a broad pharmaceutical company. It is building density in one specialty, using product-rights transactions and a focused commercial organization to make the same physician call point more productive across multiple brands. The company’s commercial footprint is primarily in the United States, although manufacturing and licensing relationships can extend internationally. For FY2024, revenue was #N/A, reflecting Harrow’s transition toward a broader branded ophthalmic portfolio.

Harrow at a Glance

Logo
Common name	Harrow
Full legal name	Harrow, Inc.
Headquarters	Nashville, Tennessee, United States
Ownership	Public company
Ticker	HROW
Exchange	NASDAQ
Market Cap	$1.59B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Roots trace to 2006; public-company evolution through Imprimis Pharmaceuticals; renamed Harrow Health in 2018; renamed Harrow, Inc. in 2022; expanded branded ophthalmic portfolio materially in 2023-2024 through multiple product-rights transactions.
Industry or industries	Ophthalmic pharmaceuticals; specialty pharmaceuticals; prescription eye care
Key products or services	Prescription ophthalmic medicines including dry-eye therapy, ocular-surface anesthesia, anti-inflammatory, anti-infective, anti-allergy, anti-fungal, and surgical/retinal-use products; legacy ophthalmic compounding through ImprimisRx
Geographic footprint	Primarily United States commercial focus, with manufacturing, supply, and licensing relationships that may include international counterparties
Business segments as officially reported	As described in recent filings, Harrow is primarily presented as a focused ophthalmic pharmaceutical business rather than a diversified multi-segment conglomerate
Company website	https://www.harrow.com

1. What Is the Strategy of Harrow?

Harrow’s public communications through 2023 and 2024 point to a clear strategic theme: build a scaled, U.S.-focused ophthalmic pharmaceutical platform by combining differentiated new products with established prescription brands, then commercialize them through a concentrated eye-care sales and market-access model. Using the Playing to Win framework, Harrow’s strategy can be described as follows.

1a. What is the winning aspiration of Harrow?

Harrow appears to define winning as becoming a more important, more durable ophthalmic pharmaceutical company in the U.S. eye-care market, not merely as a single-product launch story. Its public messaging emphasizes improving vision-related outcomes while increasing access and affordability for prescribers and patients. Strategically, that means building a portfolio that makes Harrow relevant across multiple ophthalmic use cases and gives it lasting commercial relevance with eye-care professionals.

Management materials through 2024 emphasized growth in branded ophthalmic revenue, portfolio expansion, and profitable commercialization rather than a single long-range corporate numeric target. In practice, Harrow’s aspiration seems to be a bigger branded mix, more predictable cash generation, and a stronger position as a specialist eye-care company.
1b. Where does Harrow play?

Harrow plays in prescription ophthalmology, primarily in the United States. It is focused on products prescribed, used, or stocked by ophthalmologists, optometrists, ambulatory surgery centers, hospitals, and pharmacies serving eye-care patients. The company is not trying to be a broad primary-care drug company, a consumer eye-care brand owner, or a large global pharmaceutical conglomerate.

Its chosen fields include chronic dry eye, peri-operative ophthalmology, ocular-surface anesthesia, anti-inflammatory and anti-infective therapy, allergy, fungal eye infections, and certain retinal or procedure-related uses. Harrow also has legacy roots in physician-oriented ophthalmic compounding, which historically gave it direct relationships with eye-care practices.
1c. How does Harrow plan to win?

Harrow’s apparent recipe for winning is to combine portfolio density with specialist commercial focus. Rather than fund a broad early-stage research engine, Harrow has leaned heavily on licensing and product-rights acquisitions to assemble ophthalmic assets that can be promoted through the same call points. That matters because a field force calling on ophthalmologists becomes more valuable when it can discuss multiple relevant therapies rather than one niche product.

Harrow also tries to win by selecting products where specialist promotion, continuity of supply, and market access can change the outcome. In some categories, that means differentiated products such as VEVYE or IHEEZO. In others, it means revitalizing mature but still clinically relevant brands that may have received limited promotional attention inside larger companies.
1d. What capabilities must Harrow have in place?

To execute this strategy, Harrow needs a focused set of capabilities:
- Ophthalmology-specific commercial expertise, including relationships with ophthalmologists, optometrists, and surgery centers
- Business development and licensing judgment to identify underpromoted or strategically available assets
- Regulatory, quality, and pharmacovigilance capabilities suited to sterile ophthalmic products
- Market access, reimbursement, and patient-support capabilities, especially for chronic therapies where formulary coverage affects uptake
- Supply and manufacturing oversight, because reliability matters disproportionately in ophthalmology and certain products may have limited-source manufacturing
- Portfolio management discipline so legacy brands, new launches, and acquired rights reinforce rather than distract from one another
1e. What management systems does Harrow require?

Harrow needs management systems that tie commercial execution, access, and supply together. For a company with multiple acquired and licensed brands, core systems likely include launch tracking, prescriber and territory analytics, gross-to-net monitoring, inventory and service-level management, quality and compliance oversight, and return-on-promotion measurement by product.

Just as important is capital-allocation discipline. Because Harrow’s model depends heavily on product-rights transactions, management must decide continuously whether cash should go to a new asset, a launch investment, supply reinforcement, or balance-sheet support. In a focused specialty pharma company, those decisions are central strategic systems, not back-office finance tasks.

2. What Are the Current Strategic Initiatives of Harrow?

Based on company communications through 2023 and 2024, Harrow’s current strategic initiatives are highly practical and product-centered.

Scale VEVYE in dry eye disease. VEVYE is strategically important because chronic dry eye is a large prescription category with repeat-script potential. Harrow’s work has included launch execution, physician education, patient access support, and formulary/reimbursement efforts.
Build adoption of IHEEZO in procedure settings. IHEEZO gives Harrow a differentiated position in ocular-surface anesthesia for procedures. That requires targeted selling to physicians and surgery settings where product workflow, stocking, and familiarity matter.
Reinvigorate acquired legacy ophthalmic brands. Harrow’s rights transactions with larger pharmaceutical companies expanded its portfolio with established prescription brands. The strategic task is not basic awareness creation; it is dependable supply, focused promotion, pricing and access management, and getting those products back into the routine prescribing conversation.
Use one sales footprint across more products. Portfolio breadth is only valuable if Harrow can raise sales-force productivity. A major initiative is therefore call-point leverage: more revenue per ophthalmology account, better cross-selling, and more efficient territory coverage.
Strengthen supply continuity for ophthalmic products. In ophthalmology, supply interruptions can quickly damage physician trust. Harrow’s repeated emphasis on portfolio execution implies that manufacturing oversight and inventory reliability are strategic, not merely operational.
Continue selective business development. Harrow’s strategy suggests that additional ophthalmic licensing or product-rights deals remain part of the playbook where assets fit existing call points and can be commercialized with the current platform.
Shift the mix toward branded products. Relative to its compounding heritage, Harrow’s more recent strategic direction has favored higher-value branded prescription products with greater commercial scalability.

3. What Is the Business Model of Harrow?

Harrow’s business model is that of a focused specialty pharmaceutical company centered on ophthalmology. Customers do not buy “Harrow” as a platform; they buy prescription eye-care products for specific clinical needs. Those needs range from chronic dry eye therapy to peri-operative inflammation control, ocular-surface anesthesia, infection management, allergy treatment, fungal infections, and certain retinal or surgical uses.

What customers actually buy

Eye-care professionals and the channels that serve them buy clinically specific products: a chronic dry-eye prescription, an anesthetic used in a procedure, a post-operative anti-inflammatory, an anti-infective drop, or another ophthalmic therapy. End patients buy symptom relief, better procedural workflow, or continuity of clinically established treatment.

Recurring or repeat-driven versus one-time

Most of Harrow’s model is repeat-driven rather than one-time. Chronic dry-eye therapy can generate refill behavior. Mature ophthalmic brands can produce recurring prescriptions. Procedure-related products repeat with surgical volume. Even legacy compounded formulations tend to be reorder-driven in physician practices. Harrow is not a project business and not a device company with one-time capital sales.

How pricing power works

Pricing power varies sharply by product. Differentiated branded therapies and hard-to-source ophthalmic products can have better pricing support, especially where clinical workflow or formulation matters. But Harrow’s pricing freedom is still constrained by payer coverage, copay affordability, generic substitutes, and physician prescribing habits. In mature categories, supply reliability and service can matter as much as list price.

Why the business mix matters

Mix is critical. Established brands can provide a cash-generating base and keep the sales force relevant across more visit types. Newer growth brands can create upside, but they typically require heavier selling and access investment. Chronic therapies behave differently from procedure products, and each supports the portfolio in a different way.

What drives gross margin, operating margin, and cash generation

Gross margin is shaped by product mix, manufacturing cost, royalties or profit-share terms embedded in licensing arrangements, and gross-to-net deductions such as rebates, chargebacks, and copay support. Operating margin depends heavily on how much Harrow spends on launches, field sales, market access, medical affairs, and corporate overhead. Cash generation depends on inventory management, receivables collection, launch working capital, and whether product-rights deals require up-front payments or milestone obligations.

Revenue model

Harrow’s revenue model is primarily prescription product sales, not subscription, freemium, or usage-based software. Some products move through retail or specialty pharmacies; some are relevant to office and surgical workflows; legacy compounding has included direct physician-ordering behavior. The common thread is repeat clinical use within ophthalmology.

4. What Products and Services Does Harrow Sell?

Harrow sells prescription ophthalmic products and related ophthalmic pharmaceutical services. By 2024, the portfolio had become materially broader than the company’s earlier compounding identity.

VEVYE. A branded dry-eye therapy and one of Harrow’s most strategically important growth assets because it addresses a large chronic-use category.
IHEEZO. A branded ocular-surface anesthetic gel for use in procedures, giving Harrow a differentiated product in ophthalmic workflow.
Established branded ophthalmic products. Harrow’s expanded portfolio includes products used in anti-inflammatory, anti-infective, anti-allergy, anti-fungal, and surgical settings. Publicly discussed products in its broadened brand set have included names such as FLAREX, NATACYN, TOBRADEX ST, ZERVIATE, ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE.
Legacy ophthalmic compounding and physician-directed formulations. Harrow historically built relationships through ImprimisRx, which supplied compounded ophthalmic products used by eye-care practices.

From a strategic standpoint, the most important offerings are the ones that can either scale materially or strengthen the sales-force value proposition. VEVYE fits the first category. IHEEZO fits the second by giving Harrow a differentiated product at the procedural call point. The acquired legacy brands matter because they add breadth, support sales productivity, and can contribute cash flow if supply and promotion are managed well.

The portfolio also shows a meaningful distinction between legacy relationship products and newer branded growth products. Harrow’s long-term economic profile likely depends more on the branded side.

5. What Are the Key Competitors or Peers of Harrow?

Harrow competes product by product rather than against one single universal rival. Its closest peers are companies with meaningful ophthalmic pharmaceutical franchises or similar specialist-commercial models.

Bausch + Lomb. A broad eye-health company with branded ophthalmic pharmaceuticals and strong commercial presence across eye care. Relevant in dry eye and adjacent prescription categories.
AbbVie. Through legacy ophthalmic products such as Restasis, AbbVie remains an important comparator in dry eye and branded ophthalmology.
Alcon. More device- and surgical-heavy than Harrow, but it competes for mindshare with ophthalmologists and surgery centers and is influential at the same call points.
Santen Pharmaceutical. A dedicated ophthalmology company globally, and an important peer for how specialist eye-care pharmaceutical portfolios are built and commercialized.
Sun Pharmaceutical / Sun Ophthalmics. Relevant especially in dry eye and other branded ophthalmic categories.
Viatris. A major generic competitor in mature ophthalmic formulations, especially where branded products face substitution pressure.
Amneal Pharmaceuticals. Relevant as a generic and specialty pharmaceutical competitor in ophthalmic molecules where price competition matters.
Teva Pharmaceuticals. Another broad pharmaceutical competitor whose generic capabilities can matter in ophthalmic categories with mature molecules.
Ocular Therapeutix. A smaller but important ophthalmology-focused peer with specialized products and a concentrated commercial model.
EyePoint Pharmaceuticals. More retina- and innovation-oriented, but still a useful ophthalmic specialty peer for investors and industry observers comparing focused eye-care platforms.

In practice, Harrow’s toughest competition often comes from a mix of branded incumbents in specific indications and generic manufacturers in mature categories. That is why portfolio selection, access, and supply reliability matter so much.

6. What Is the Marketing Strategy of Harrow?

Harrow’s marketing strategy appears to be primarily specialist, physician-centered, and field-driven. This is not a mass-market consumer brand model. The key audience is eye-care professionals, with patients reached mainly through prescribing behavior, affordability programs, and pharmacy fulfillment.

Several elements stand out:

Targeted professional promotion. Marketing is built around ophthalmologists, optometrists, and procedure-oriented practices rather than general practitioners.
Portfolio marketing at the call point. Because Harrow sells multiple ophthalmic brands, part of the marketing logic is call-point efficiency: one rep relationship can support several clinically distinct products.
Access and affordability as commercial messaging. For products such as chronic dry-eye therapies, reimbursement support, copay economics, and fulfillment simplicity can be as important as clinical messaging.
Educational and workflow-oriented selling. Products used in surgery or office procedures require adoption support tied to workflow, familiarity, and stocking behavior.
Brand maintenance for mature products. Older ophthalmic brands typically need focused reminder marketing, dependable supply, and channel support rather than heavy consumer advertising.

Marketing does not appear to be Harrow’s main strategic differentiator in the consumer packaged-goods sense. The bigger differentiators are portfolio choice, specialist sales coverage, and commercialization discipline. Marketing is an important enabling capability that helps those advantages convert into prescriptions and orders.

7. What Are the Key Customer Segments of Harrow?

Harrow’s customer base is concentrated rather than broadly diversified. That concentration is a strategic feature: the company is focused on eye care.

Ophthalmologists. This is the core prescriber group for many of Harrow’s products, particularly surgical, retinal, and more specialized ophthalmic therapies.
Optometrists. Important especially in dry eye, allergy, and broader office-based eye-care prescribing.
Ambulatory surgery centers and hospital-based eye-surgery settings. Critical for products tied to procedures, peri-operative care, and in-office usage.
Pharmacies and specialty pharmacies. These are channel customers that affect fulfillment, refill persistence, and patient experience.
Wholesalers and distributors. They are not the ultimate clinical decision-makers, but they matter for market access and product availability.
Patients. Patients are the end users and the economic reality behind persistence, affordability, and therapy choice, especially in chronic dry eye.

Harrow is therefore not diversified across many unrelated end markets. Its fortunes are closely tied to ophthalmology prescribing patterns, procedure volumes, reimbursement, and supply reliability in a relatively narrow specialty.

8. What Is the Sales Model of Harrow?

Harrow uses a specialty-pharma sales model focused on the U.S. eye-care ecosystem. The company appears to sell through a mix of direct field promotion, pharmacy channels, and institutional ordering pathways depending on the product.

Direct sales force. Harrow’s commercial model relies on representatives calling on ophthalmologists, optometrists, and surgery-related accounts.
Pharmacy-based fulfillment. For prescription products such as chronic therapies, the physician writes the prescription and the product is dispensed through retail or specialty pharmacy channels.
Office and procedural channel support. Products tied to surgery or in-office procedures require account-level selling, workflow education, and stocking support.
Legacy direct physician-ordering behavior. The company’s historical ImprimisRx business involved direct physician relationships that are somewhat different from traditional retail-prescription selling.

This channel structure shapes growth and pricing. A focused direct-sales model can create strong customer intimacy within ophthalmology, but it also means commercial productivity matters enormously. Each additional product needs to justify its place in the bag. At the same time, pharmacy and payer channels influence net pricing, patient access, and refill behavior. That makes Harrow’s sales model a blend of specialist field execution and channel management rather than pure direct selling.

9. In What Geographies Does Harrow Operate?

Harrow’s commercial focus is overwhelmingly the United States. Its headquarters are in Nashville, Tennessee, and its sales and commercial activities are designed around the U.S. ophthalmology market. That means U.S. physician relationships, U.S. reimbursement, U.S. pharmacy distribution, and U.S. regulatory requirements are the central operating realities.

The company’s geographic footprint is therefore narrower than that of a large global pharmaceutical company. Harrow does not appear to have a broad direct-selling presence across Europe, Asia, or Latin America. However, some manufacturing, supply, and licensing relationships may involve counterparties outside the U.S., which is common in specialty pharmaceuticals.

Strategically, this concentration has advantages and risks. It gives Harrow focus in one of the world’s most valuable prescription markets, but it also means the company is more exposed to U.S. payer dynamics, FDA-related supply issues, and the performance of a single national commercial organization.

10. Who Are the Owners of Harrow?

Harrow is a publicly traded company, so ownership changes over time. In public filings around 2024, the company did not disclose a controlling shareholder. Ownership appeared to be a mix of insiders and institutional investors.

CEO Mark L. Baum has historically been a notable insider shareholder. Public filings and market disclosures have also shown positions held by institutional investors, including large asset managers such as BlackRock and Vanguard, alongside healthcare-focused funds. As with any public company, exact holdings are time-sensitive and should be checked against the latest proxy statement and SEC filings for current percentages.

11. How Is Harrow Organized?

Practically, Harrow is organized as a focused ophthalmic pharmaceutical platform rather than a diversified operating conglomerate. As presented in recent filings, the business is centered on prescription ophthalmic products, with shared functions supporting the portfolio.

At an operating level, the structure appears to include:

Commercial and sales. Field teams and brand support aimed at eye-care professionals and relevant accounts.
Market access and patient services. Important for reimbursement-heavy products and pharmacy fulfillment.
Medical affairs, regulatory, quality, and pharmacovigilance. Core control functions for a regulated pharmaceutical company.
Supply chain and manufacturing oversight. Especially important because Harrow relies heavily on third-party production and product-rights arrangements.
Business development. A strategically important capability given the company’s reliance on licensing and acquisition of product rights.

Harrow has also historically had relationships with affiliated or investee ophthalmic companies. Those interests may be strategically useful, but the organizational center of gravity is the U.S. ophthalmic commercial platform.

12. How Does Harrow Operate?

Day to day, Harrow operates like a specialist pharmaceutical commercializer. It does not primarily create value by running a giant internal research engine or a massive owned manufacturing network. Instead, it creates value by selecting the right ophthalmic assets, securing supply, and driving focused execution in the market.

The operating cycle usually looks something like this:

Source or develop an asset. Harrow identifies a product to acquire, license, or selectively develop.
Secure regulatory and supply readiness. That includes manufacturing oversight, quality systems, validation, inventory planning, labeling, and compliance.
Contract with channels and support access. Products then need the right wholesaler, pharmacy, payer, and patient-support setup.
Promote to eye-care professionals. Sales reps, medical education, and account support drive prescribing and ordering behavior.
Monitor persistence, demand, and service levels. For chronic therapies that means refill and access metrics; for procedure products it means account activation and reorder rates.

Operational complexity comes from the interaction of regulation, specialty selling, and supply. Ophthalmic products can be clinically important but commercially small enough that one manufacturing problem or one access bottleneck has an outsized effect. That makes forecasting, quality, and launch discipline unusually important for Harrow.

13. What Are the Growth Opportunities for Harrow?

Harrow’s most plausible growth opportunities come from a mix of organic portfolio expansion and continued dealmaking inside ophthalmology.

Scaling VEVYE. Dry eye is a large market, and a successful launch can create recurring prescription economics if access and persistence improve.
Expanding procedural adoption of IHEEZO. Because IHEEZO is tied to clinical workflow, broader account penetration could drive attractive repeat use.
Reactivating underpromoted brands. Harrow may be able to grow established products through better field focus, supply continuity, and channel attention than they received inside larger portfolios.
Cross-selling across the same call points. As the portfolio broadens, sales-force productivity can improve if one rep can support more clinically relevant products in each eye-care account.
Additional ophthalmic licensing and product-rights transactions. This is a natural extension of Harrow’s strategy, especially where products fit existing physician relationships.
Leveraging affiliated innovation. Where Harrow has relationships with adjacent ophthalmic ventures, those can provide option value for future products or commercialization rights.
Improving payer access and patient affordability. Better reimbursement can unlock growth without requiring a new product.

Main constraints include payer friction in dry eye, generic competition in mature categories, dependence on third-party manufacturing, limited scale relative to larger pharma competitors, and the capital demands of launches and product-rights deals. In other words, Harrow has visible runway, but execution risk remains high because the company is concentrated in one specialty and leans heavily on a portfolio model.

14. What Is the History of Harrow?

Harrow traces its roots to 2006 and the business that became known publicly as Imprimis Pharmaceuticals. The company’s early identity was tied heavily to compounded medicines, particularly in ophthalmology, and the broader platform was built under the leadership of Mark L. Baum. Through the 2010s, the business became increasingly associated with ophthalmic compounding and physician-dispensed eye-care formulations.

A major turning point came when the company rebranded as Harrow Health in 2018, reflecting a broader strategic identity. In 2022 it simplified that name further to Harrow, Inc., by which point ophthalmology had become the core focus.

The next major chapter was portfolio building. During 2022 through 2024, Harrow used a series of product-rights transactions and licensing arrangements to acquire or commercialize a significantly larger branded ophthalmic portfolio, including assets such as IHEEZO and VEVYE and a set of established ophthalmic brands acquired from larger pharmaceutical companies. That shifted the company’s strategic profile from a narrower compounding-based story toward a more conventional, though still highly focused, specialty-pharmaceutical model in eye care.

15. What Are the Key Suppliers to Harrow?

Suppliers matter a great deal to Harrow because ophthalmic pharmaceuticals depend on regulated manufacturing, validated quality systems, and dependable distribution. For Harrow, the most important suppliers are not commodity vendors; they are specialized operating partners.

Contract manufacturers. Sterile ophthalmic products often require specialized fill-finish, formulation, packaging, and quality capabilities.
Active pharmaceutical ingredient suppliers. Reliable sourcing of APIs and excipients matters, especially where products have limited approved supply chains.
Packaging and labeling partners. Ophthalmic products require controlled packaging, lot traceability, and regulatory accuracy.
Licensors and transition partners. In product-rights deals, the counterparty may remain strategically important during tech transfer, supply handoff, or ongoing manufacturing support.
Logistics and distribution providers. Pharmaceutical wholesalers, third-party logistics providers, and specialty pharmacy infrastructure all influence product availability.

Supplier structure matters strategically because Harrow is not a vertically integrated manufacturer on the scale of large pharma. If a key CMO, API source, or transition partner fails to perform, Harrow can lose sales quickly and, more importantly, lose physician trust. In ophthalmology, prescribers often remember supply reliability.

16. What Are the Key Brands Owned by Harrow?

Brands are important to Harrow, but in a specialist-clinician sense rather than a consumer packaged-goods sense. The value of a brand here comes from physician familiarity, clinical role, access, and confidence in supply.

VEVYE. Harrow’s flagship growth brand in chronic dry eye. Strategically important because it can expand Harrow’s presence in a large prescription category with refill behavior.
IHEEZO. A differentiated procedural ophthalmic brand tied to anesthesia during ocular-surface procedures. Its brand value rests on workflow utility and specialist familiarity.
TRIESENCE. Important because it sits in an area where product availability and clinical need can matter more than broad consumer brand awareness.
Established topical brands. Harrow’s portfolio of acquired ophthalmic brands includes products used in anti-inflammatory, anti-infective, anti-allergy, and anti-fungal settings. These brands are valuable because many eye-care professionals already know the names, even if prior owners did not emphasize promotion.
ImprimisRx. More a service and relationship brand than a classic branded-drug franchise, but historically important to Harrow’s identity and physician connectivity.

For Harrow, brand strength is closely tied to continuity, clinical relevance, and whether the product remains easy to prescribe, dispense, and obtain. The company’s challenge is to turn known ophthalmic names into commercially productive assets again.

17. How Does the Supply Chain of Harrow Function?

Harrow’s supply chain is typical of a focused specialty pharmaceutical company: externally sourced, tightly regulated, and highly sensitive to disruptions. Because many ophthalmic products are sterile or otherwise technically demanding, the supply chain is strategically important.

Rights and product ownership. Harrow secures commercial rights through acquisition, licensing, or development arrangements.
Manufacturing and sourcing. Third-party manufacturers produce finished product, drawing on approved APIs, excipients, packaging, and quality systems.
Quality release and compliance. Batches must meet regulatory specifications, with documentation, release procedures, and pharmacovigilance controls in place.
Warehousing and distribution. Product moves through pharmaceutical logistics providers and on to wholesalers, pharmacies, or accounts depending on the channel.
Fulfillment to the point of care. Some products are dispensed through pharmacy channels to patients; others are ordered for office or procedural use.

Three things make the supply chain strategically important for Harrow. First, ophthalmic prescribers are sensitive to stock-outs. Second, a relatively small company has less redundancy than a large pharma group. Third, acquired brands can come with transition complexity, especially if manufacturing is being transferred or re-established. As a result, sourcing resilience, inventory discipline, and tech-transfer execution are central to performance.

18. What Major Acquisitions Has Harrow Made?

Acquisitions are important to Harrow, but the company’s pattern is better described as product-rights acquisition and licensing than as traditional whole-company mergers. That distinction matters because Harrow’s strategy is to build a focused portfolio, not to assemble a large corporate empire.

IHEEZO rights transaction. Harrow added IHEEZO as part of its move into differentiated branded ophthalmic products tied to procedures.
VEEVYE commercialization rights. Harrow’s involvement with VEVYE reflects the company’s interest in larger chronic ophthalmic categories where a specialist commercial model can create scale.
Santen portfolio transaction. Harrow expanded its portfolio with established U.S. ophthalmic brands associated with Santen, broadening its relevance across multiple eye-care categories.
Novartis ophthalmic brand transaction. Harrow also acquired rights to a set of established ophthalmic brands from Novartis, adding breadth in anti-inflammatory, anti-infective, and procedure-related products.

The strategic role of these deals is clear: they allow Harrow to add revenue-producing assets that fit existing eye-care call points without taking on the cost and uncertainty of a large internal research program. The trade-off is that integration, supply continuity, and commercial prioritization become management-critical. Harrow’s recent history suggests that M&A for this company is less about corporate scale and more about portfolio assembly.

19. How Companies Like Harrow Leverage Independent Consultants through Umbrex

Companies like Harrow often need highly specialized strategic help without hiring a full global consulting team. Umbrex has built a global community of more than 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like Harrow engage Umbrex when they want that level of training and judgment but need a leaner, more targeted model. Umbrex consultants span strategy, operations, organization, marketing, sales, finance, technology, ERP, and AI.

For a company like Harrow, representative Umbrex projects could include:

Dry-eye market strategy work for VEVYE, including indication economics, prescriber segmentation, and competitive-response planning
Sales-force sizing, territory design, and call-point productivity analysis across ophthalmology and optometry
Market-access strategy, including gross-to-net diagnostics, channel economics, and affordability-program redesign
Commercial due diligence on ophthalmic licensing or product-rights acquisition targets
Post-acquisition integration planning for newly acquired ophthalmic brands, including supply, pricing, and brand-prioritization decisions
Key opinion leader mapping and customer-journey redesign for procedure-based products such as IHEEZO
Portfolio strategy work to decide which legacy brands deserve incremental promotion, which should be maintained for cash flow, and which may need restructuring
Supply-chain risk assessment for sterile ophthalmic products, including dual-source options, inventory strategy, and service-level controls
Patient-support and hub-services redesign to reduce prescription abandonment and improve refill persistence in chronic therapies
AI-enabled forecasting and CRM analytics to improve launch tracking, demand planning, and next-best-action guidance for the field force